Abstract: The present disclosure relates to a radiopharmaceutical compositions, methods, and kits comprising 177Lu-PSMA I&T. The composition may be formulated as a solution for injection and the solution is suitable for administration at least 72 hours after formulation. The composition(s) have a radiochemical purity (RCP) of 95% or greater, 95.5% or greater, 96% or greater, 96.5% or greater, 97% or greater, 97.5% or greater, 98.0% or greater, 98.5% or greater, 99% or greater, or 99.5% or greater at administration.

Abstract: The present disclosure relates to concentrated and stable parenteral 177Lutetium-DOTA-TATE radionuclide complex solutions. Drug stability is achieved by the combination of from 5 mg/mL to 25 mg/mL of ascorbic acid or a salt thereof and from 1 v/v % to 3 v/v % ethanol.

Abstract: The present disclosure relates to a pharmaceutical composition comprising 177Lu-PSMA I&T and methods of administering the same. The administration of the composition results in a low absorbed radiation dose per gram of tissue in a human patient's body, including the kidneys, gastrointestinal tract, left colon, liver, rectum, red marrow, spleen, lacrimal glands, and salivary glands.

Abstract: The present disclosure relates to a pharmaceutical composition comprising 177Lu-PSMA I&T and methods of administering the same. The administration of the composition results in a low absorbed radiation dose per gram of tissue in a human patient's body, including the kidneys, gastrointestinal tract, left colon, liver, rectum, red marrow, spleen, lacrimal glands, and salivary glands.

Abstract: The present disclosure relates to a pharmaceutical composition comprising 177Lu-PSMA I&T and methods of administering the same. The administration of the composition results in a low absorbed radiation dose per gram of tissue in a human patient's body, including the kidneys, gastrointestinal tract, left colon, liver, rectum, red marrow, spleen, lacrimal glands, and salivary glands.

Abstract: The present disclosure relates to a pharmaceutical composition comprising 177Lu-PSMA I&T and methods of administering the same. The administration of the composition results in a low absorbed radiation dose per gram of tissue in a human patient's body, including the kidneys, gastrointestinal tract, left colon, liver, rectum, red marrow, spleen, lacrimal glands, and salivary glands.

Abstract: The present disclosure relates to a radiopharmaceutical compositions, methods, and kits comprising 177Lu-PSMA I&T. The compositions, methods, and kits may have a molar ratio of the PSMA I&T to 177Lu from greater than 8.0:1.0 to 11.0:1.0. The composition may be formulated as a solution for injection and the solution is suitable for administration at least 72 hours after formulation. The composition(s) have a radiochemical purity (RCP) of 95% or greater, 95.5% or greater, 96% or greater, 96.5% or greater, 97% or greater, 97.5% or greater, 98.0% or greater, 98.5% or greater, 99% or greater, or 99.5% or greater at administration.

Abstract: The present disclosure provides a method of detecting prostate cancer in a human subject wherein the human subject is administrated about 7 mCi to about 9 mCi of a Cu-64 PSMA I&T composition, images are obtained between 1 and 4 hours post administration, and wherein the images obtained retain acceptable image quality up to 4 hours post dose.

Abstract: The present disclosure relates to a pharmaceutical composition comprising 177Lu-PSMA I&T and methods of administering the same. The administration of the composition results in a low absorbed radiation dose per gram of tissue in a human patient's body, including the kidneys, gastrointestinal tract, left colon, liver, rectum, red marrow, spleen, lacrimal glands, and salivary glands.

Abstract: The present disclosure relates to a radiopharmaceutical compositions, methods, and kits comprising 177Lu-PSMA I&T. The compositions, methods, and kits may have a molar ratio of the PSMA I&T to 177Lu from 4.4:1.0 to 7.6:1.0. The composition may be formulated as a solution for injection and the solution is suitable for administration at least 72 hours after formulation. The composition(s) have a radiochemical purity (RCP) of 95% or greater, 95.5% or greater, 96% or greater, 96.5% or greater, 97% or greater, 97.5% or greater, 98.0% or greater, 98.5% or greater, 99% or greater, or 99.5% or greater at administration.

Abstract: The present disclosure relates to a pharmaceutical composition comprising 177Lu-PSMA I&T and methods of administering the same. The administration of the composition results in a low absorbed radiation dose per gram of tissue in a human patient's body, including the kidneys, gastrointestinal tract, left colon, liver, rectum, red marrow, spleen, lacrimal glands, and salivary glands.

Abstract: The present disclosure generally relates to a radiopharmaceutical composition comprising 177Lu-PSMA I&T. The composition is formulated as a solution for injection and the solution is suitable for administration more than 72 hours after formulation. The composition may include ascorbic acid and have a pH of 3.5 to 4.5 in solution. In some examples, the composition is suitable for administration to a human patient in need thereof at least 90 hours after formulation, and the composition has a radiochemical purity of 95% or greater at administration.

Abstract: The present disclosure provides radiopharmaceutical composition comprising copper-64 that performs as a targeted diagnostic PET-agent. The radiopharmaceutical composition disclosed herein has a short physical half-life of about 12.7 h.